DNA Damage Response – An Emerging Target for Groundbreaking Cancer Therapies
Introduction Presented by Sean Bohen Oncology is one of the cornerstone therapeutic areas for AstraZeneca, and within the AstraZeneca oncology drug discovery platform there are four main research areas: tumour drivers and resistance, immuno-oncology, antibody conjugates and the DNA damage response (DDR). The pursuit of oncology drugs targeted at the DDR is based on tumour […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!